tiprankstipranks
Xvivo Perfusion AB (SE:XVIVO)
:XVIVO
Want to see SE:XVIVO full AI Analyst Report?

Xvivo Perfusion AB (XVIVO) Price & Analysis

3 Followers

XVIVO Stock Chart & Stats

kr247.80
-kr4.00(-1.61%)
At close: 4:00 PM EDT
kr247.80
-kr4.00(-1.61%)

Bulls Say, Bears Say

Bulls Say
Strong Balance SheetVery low leverage and a large equity base provide durable financial flexibility, lowering refinancing and solvency risk. This supports multi-year investments in regulatory filings, commercial scale-up and production capacity without forcing dilutive financing, enabling steadier execution.
Recurring Consumables MomentumRapid growth in EVLP disposables and thoracic sales signals expanding installed base and consumable pull-through, which drives recurring revenue tied to transplant volumes. Sustained disposables adoption strengthens revenue visibility and margin leverage as installed machines convert to ongoing consumable demand.
Improving Profitability & Cash GenerationConsistent EBITDA expansion and recent positive operating cash flow indicate the business is converting revenue to cash more reliably than prior years. A solid cash balance supports self-funding near-term growth and regulatory work, reducing dependency on external capital while margins scale with higher utilization.
Bears Say
Margin VolatilitySignificant year-to-year swings in gross and net margins reduce predictability of long-term profitability. Abdominal margin pressure from mix and pricing indicates underlying product- and geography-driven margin risk that will require operational fixes to stabilize earnings power over multiple quarters.
Services UnderperformanceA weak, low-margin services segment limits recurring revenue diversification and undermines overall margin expansion. Underutilization and capacity investments in services can persistently depress segment profitability and reduce the stickiness of customer relationships if not turned around structurally.
Regulatory And Execution Timing RiskUncertain regulatory timelines for heart CE/PMA and a paused U.S. liver path can materially delay access to large markets and the recurring consumable revenue those approvals would unlock. Such timing uncertainty also forces sustained R&D and scale-up spend, compressing near-term cash conversion and growth realization.

Xvivo Perfusion AB News

XVIVO FAQ

What was Xvivo Perfusion AB’s price range in the past 12 months?
Xvivo Perfusion AB lowest stock price was kr160.00 and its highest was kr310.40 in the past 12 months.
    What is Xvivo Perfusion AB’s market cap?
    Xvivo Perfusion AB’s market cap is kr8.78B.
      When is Xvivo Perfusion AB’s upcoming earnings report date?
      Xvivo Perfusion AB’s upcoming earnings report date is Oct 22, 2026 which is in 72 days.
        How were Xvivo Perfusion AB’s earnings last quarter?
        Xvivo Perfusion AB released its earnings results on Jul 14, 2026. The company reported kr0.65 earnings per share for the quarter, missing the consensus estimate of kr0.754 by -kr0.104.
          Is Xvivo Perfusion AB overvalued?
          According to Wall Street analysts Xvivo Perfusion AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Xvivo Perfusion AB pay dividends?
            Xvivo Perfusion AB does not currently pay dividends.
            What is Xvivo Perfusion AB’s EPS estimate?
            Xvivo Perfusion AB’s EPS estimate is 0.8.
              How many shares outstanding does Xvivo Perfusion AB have?
              Xvivo Perfusion AB has 31,499,470 shares outstanding.
                What happened to Xvivo Perfusion AB’s price movement after its last earnings report?
                Xvivo Perfusion AB reported an EPS of kr0.65 in its last earnings report, missing expectations of kr0.754. Following the earnings report the stock price went down -9.753%.
                  Which hedge fund is a major shareholder of Xvivo Perfusion AB?
                  Currently, no hedge funds are holding shares in SE:XVIVO
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    Xvivo Perfusion AB

                    Xvivo Perfusion AB (publ) is a medical technology company that creates and supplies advanced solutions for the preservation and perfusion of organs, tissues, and cells, primarily for use in transplantation. The company's global reach extends across Sweden, the United States, both North and South America, Europe, the Middle East, Africa, and the Asia Pacific region. Its product line includes the XVIVO System (XPS), an integrated, ready-to-use cardiac bypass system designed to facilitate safe normothermic ex vivo lung perfusion (EVLP). To support this, the XPS Disposable Lung Kit offers all the necessary sterile, pre-packed components for EVLP procedures. Xvivo also provides STEEN Solution, an optimally formulated buffered extracellular solution specifically for perfusing isolated donor lungs during EVLP. Additional offerings comprise Perfadex Plus, an extracellular, low-potassium, dextran-based electrolyte preservation solution, and the XVIVO Silicone Tubing Set, used for efficient flushing of donor lungs during the procurement process. The company also manufactures the XVIVO LS and XVIVO Disposable Lung Set, both critical devices for EVLP. Furthermore, Xvivo provides the XVIVO Organ Chamber, a sterile, single-use disposable container for temporarily housing isolated lungs before transplantation, and the XVIVO Lung Cannula Set, another sterile, single-use disposable medical product. Established in 1998, Xvivo Perfusion AB (publ) is headquartered in Gothenburg, Sweden.

                    Xvivo Perfusion AB (XVIVO) Earnings & Revenues

                    XVIVO Company Deck

                    XVIVO Earnings Call

                    Q2 2026
                    0:00 / 0:00
                    Earnings Call Sentiment|Positive
                    The call presents a predominantly positive operational and financial picture: strong organic revenue growth (36% in Q2), robust profitability (19% Q2 EBITDA margin; rolling 12-month EBITDA 21%) and improving cash generation (positive operating cash flow and SEK 305m cash balance). Commercial momentum is broad-based (notably thoracic/EVLP, kidney, and heart pre-launch adoption) and supported by strong clinical evidence (heart trial outcomes and >600 heart transplants). Key risks include services underperformance, margin pressure in abdominal products driven by mix and pricing, elevated R&D/CapEx and regulatory timing uncertainty (CE mark and U.S. pathways). Overall the positive growth, profitability and clinical/regulatory progress outweigh the identifiable execution and timing risks.View all SE:XVIVO earnings summaries
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Getinge
                    Vitrolife AB
                    CellaVision AB
                    Paxman AB
                    Sedana Medical AB
                    Popular Stocks